Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs.

Infantile fibrosarcoma (IFS) represents the most common non-rhabdomyosarcoma soft tissue tumor, with 80% of diagnoses under the first year of life. In contrast with adult fibrosarcoma, IFS has lower ...

Victor Sung, M.D., director of the Division of Movement Disorders in the University of Alabama at Birmingham Department of Neurology and director of the UAB Huntington’s Disease Clinic, reacted to the ...

With informed consent, you generally have the right to seek a second opinion or refuse treatment unless refusing poses a danger to the community or a court of law declares you “mentally incompetent.” ...

Here is described a case of ameloblastic fibrosarcoma (AFS) affecting the posterior mandible of a woman who was treated surgically and recovered without signs of recurrence or metastasis after 12 ...

The research into cardiac tumors can be traced back to the 18th century, when Bonet first introduced the relevant concept. It was not until 1936 that the first successful resection of a cardiac tumor ...

At a median follow-up of 41.3 months, the median time to progression was not reached in patients who stopped taking larotrectinib. Certain pediatric sarcoma patients can stop larotrectinib treatment ...

Study demonstrated that a previously approved drug could replace chemotherapy as a first-line therapy for certain cancers IFS, a rare soft-tissue sarcoma, typically presents as a localized tumor.

TAMPA, Fla. (AP) — Josh Norris scored twice, Rasmus Dahlin had a goal and two assists and the Buffalo Sabres beat the Tampa Bay Lightning 6-2 on Satu... Please help local businesses by taking an ...